These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 26201840)

  • 1. Antisense- and siRNA-mediated inhibition of the anti-apoptotic gene Bcl-xL for chemosensitization of bladder cancer cells.
    Rieger C; Huebner D; Temme A; Wirth MP; Fuessel S
    Int J Oncol; 2015 Sep; 47(3):1121-30. PubMed ID: 26201840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. siRNA-mediated inhibition of antiapoptotic genes enhances chemotherapy efficacy in bladder cancer cells.
    Kunze D; Erdmann K; Froehner M; Wirth MP; Fuessel S
    Anticancer Res; 2012 Oct; 32(10):4313-8. PubMed ID: 23060552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced inhibition of bladder cancer cell growth by simultaneous knockdown of antiapoptotic Bcl-xL and survivin in combination with chemotherapy.
    Kunze D; Erdmann K; Froehner M; Wirth MP; Fuessel S
    Int J Mol Sci; 2013 Jun; 14(6):12297-312. PubMed ID: 23749114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic delivery of siRNA specific to tumor mediated by atelocollagen: combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer.
    Mu P; Nagahara S; Makita N; Tarumi Y; Kadomatsu K; Takei Y
    Int J Cancer; 2009 Dec; 125(12):2978-90. PubMed ID: 19422046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multitarget siRNA inhibition of antiapoptotic genes (XIAP, BCL2, BCL-X(L)) in bladder cancer cells.
    Kunze D; Wuttig D; Fuessel S; Kraemer K; Kotzsch M; Meye A; Grimm MO; Hakenberg OW; Wirth MP
    Anticancer Res; 2008; 28(4B):2259-63. PubMed ID: 18751404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemosensitization of bladder cancer cells by survivin-directed antisense oligodeoxynucleotides and siRNA.
    Fuessel S; Herrmann J; Ning S; Kotzsch M; Kraemer K; Schmidt U; Hakenberg OW; Wirth MP; Meye A
    Cancer Lett; 2006 Feb; 232(2):243-54. PubMed ID: 16458121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous siRNA-mediated knockdown of antiapoptotic BCL2, Bcl-xL, XIAP and survivin in bladder cancer cells.
    Kunze D; Kraemer K; Erdmann K; Froehner M; Wirth MP; Fuessel S
    Int J Oncol; 2012 Oct; 41(4):1271-7. PubMed ID: 22797576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation.
    Ni F; Yan CY; Zhou S; Hui PY; Du YH; Zheng L; Yu J; Hu XJ; Zhang ZG
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):593-605. PubMed ID: 30032449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo.
    Kunze D; Wuttig D; Kausch I; Blietz C; Blumhoff L; Burmeister Y; Kraemer K; Fuessel S; Toma M; Schwenzer B; Meye A; Grimm MO; Hakenberg OW; Jocham D; Wirth MP
    Int J Oncol; 2008 May; 32(5):1049-56. PubMed ID: 18425331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MLN4924 Synergistically Enhances Cisplatin-induced Cytotoxicity via JNK and Bcl-xL Pathways in Human Urothelial Carcinoma.
    Ho IL; Kuo KL; Liu SH; Chang HC; Hsieh JT; Wu JT; Chiang CK; Lin WC; Tsai YC; Chou CT; Hsu CH; Pu YS; Shi CS; Huang KH
    Sci Rep; 2015 Nov; 5():16948. PubMed ID: 26592553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells.
    Kraemer K; Fuessel S; Schmidt U; Kotzsch M; Schwenzer B; Wirth MP; Meye A
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3794-800. PubMed ID: 14506173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bcl-XL and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis.
    Brotin E; Meryet-Figuière M; Simonin K; Duval RE; Villedieu M; Leroy-Dudal J; Saison-Behmoaras E; Gauduchon P; Denoyelle C; Poulain L
    Int J Cancer; 2010 Feb; 126(4):885-95. PubMed ID: 19634140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement effect of adenovirus-mediated antisense c-myc and caffeine on the cytotoxicity of cisplatin in osteosarcoma cell lines.
    Xie XK; Yang DS; Ye ZM; Tao HM
    Chemotherapy; 2009; 55(6):433-40. PubMed ID: 19996588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth.
    Ning S; Fuessel S; Kotzsch M; Kraemer K; Kappler M; Schmidt U; Taubert H; Wirth MP; Meye A
    Int J Oncol; 2004 Oct; 25(4):1065-71. PubMed ID: 15375557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of either YY1 or BclXL-induced inhibition by the NO-donor DETANONOate in the reversal of drug resistance, both in vitro and in vivo. YY1 and BclXL are overexpressed in prostate cancer.
    Huerta-Yepez S; Baritaki S; Baay-Guzman G; Hernandez-Luna MA; Hernandez-Cueto A; Vega MI; Bonavida B
    Nitric Oxide; 2013 Feb; 29():17-24. PubMed ID: 23246440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VEGF-C inhibition reverses resistance of bladder cancer cells to cisplatin via upregulating maspin.
    Zhu H; Yun F; Shi X; Wang D
    Mol Med Rep; 2015 Aug; 12(2):3163-9. PubMed ID: 25936422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. β-Catenin signaling pathway regulates cisplatin resistance in lung adenocarcinoma cells by upregulating Bcl-xl.
    Zhang J; Liu J; Li H; Wang J
    Mol Med Rep; 2016 Mar; 13(3):2543-51. PubMed ID: 26860078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
    Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L
    Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemosensitization of solid tumors by inhibition of Bcl-xL expression using DNAzyme.
    Yu X; Yang L; Cairns MJ; Dass C; Saravolac E; Li X; Sun LQ
    Oncotarget; 2014 Oct; 5(19):9039-48. PubMed ID: 25344863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MK2206 potentiates cisplatin-induced cytotoxicity and apoptosis through an interaction of inactivated Akt signaling pathway.
    Sun D; Sawada A; Nakashima M; Kobayashi T; Ogawa O; Matsui Y
    Urol Oncol; 2015 Mar; 33(3):111.e17-26. PubMed ID: 25499922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.